AUTHORS
Jason Gotlib, MD,MS, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed2, Cristina Papayannidis, MD, PhD3, Tania Jain, MBBS4, Khalid Shoumariyeh, MD5, Isaac Goncalves, MD6, Stephen Fuller, MD7, Stephanie Lee, MD8, Juliana Schwaab, MD9, Karin Hartmann, MD10, Jenna Zhang, PhD11, Kim Dishman, MSN12, Catherine Wang, MD, PhD13, Daniel J DeAngelo, MD, PhD14
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States
2 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy
4 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
5 University of Freiburg, Freiburg, Germany
6 Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia
7 Sydney Medical School, Nepean Clinical School, University of Sydney, Kingswood, Australia
8 St. Michael's Hospital, Toronto, Canada
9 University Hospital Mannheim, Heidelberg University, Mannheim, Germany
10 University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland
11 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
12 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
13 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction
Advanced (Adv) systemic mastocytosis (SM) is a rare clonal neoplasm characterized by neoplastic mast cell infiltration in >1 extracutaneous tissue, organ damage, and decreased overall survival. Substantial symptom burden can arise, resulting in markedly impaired quality of life (QoL). Bezuclastinib is an oral, potent tyrosine kinase inhibitor (TKI) with high selectivity for KIT p.D816V, the mutated protein driving disease in up to 95% of patients. Results from the pivotal Apex study (NCT04996875) showed high rates of clinical, pathologic, and molecular responses with a well-tolerated safety profile in patients with AdvSM receiving bezuclastinib. Here, we report patient-reported outcomes (PROs) from Apex to further characterize the impact of bezuclastinib in AdvSM.
Methods
Apex is a registration-directed, phase 2, open-label study evaluating efficacy and safety of bezuclastinib 150 mg daily in patients with AdvSM, including those with aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia. Exploratory assessments of QoL and mastocytosis-associated symptoms were electronically collected through 3 questionnaires: the Mastocytosis Quality of Life Questionnaire (MC-QoL), Patient Global Impression of Severity (PGIS), and Patient Global Impression of Change (PGIC) PRO measures. MC-QoL assesses the impact of mastocytosis on QoL across symptoms, social life/functioning, emotion, and skin domains (0-100 scale, with higher scores indicating greater impairment in patient-reported QoL); PGIS (0 represents “no” symptoms, and 4 represents “very severe” symptoms) and PGIC (-3 represents “very much worse,” and 3 represents “very much better”) are categorical assessments of a patient’s current perception of disease severity and change in their disease since study baseline, respectively. Questionnaires were given at the start of treatment, every 4 weeks until week 56, and every 8 weeks thereafter until the end of treatment.
Results
A total of 81 patients received bezuclastinib 150 mg daily: median age 70 years (range, 43-87); 72% male; 35% received prior TKI therapy. Median (range) baseline serum tryptase, KIT D816V variant allele frequency (VAF) in blood, and bone marrow mast cell burden were 191 ng/mL (23-1987 ng/mL), 6.7% (0%-91.4%), and 35% (3%-95%), respectively. In the subset of patients with electronic PRO data, mean baseline MC-QoL total score was 41.3 (n=51; standard deviation [SD], 18.4), which indicated moderate impairment in patient-reported QoL. Median baseline PGIS overall symptom score was 2 (n=51; “moderate” symptoms); most patients (n/N=36/51; 71%) reported scores ranging from 2 to 4, consistent with “moderate” to “very severe” symptoms at baseline.
At data cutoff (31 March 2026), median (range) overall treatment duration was 63 weeks (1-135). Mean best percent reduction from baseline in MC-QoL total score was 72% (n=50; standard error [SE], 3), indicating improvement with treatment. Mean percent reduction in MC-QoL total score of 36% (n=46; SE, 6) was observed at week 4 and deepened over time, with a mean percent reduction of 54% (n=23; SE, 7) at week 52. Results across MC-QoL domains were consistent with the total score. Based on PGIS, mean best percent reduction in overall symptoms was 77% (n=48; SE, 5); 86% (n/N=43/50) of patients reported any improvement from baseline (≥1 point decrease). 58% (31/53) of patients at week 4 and 80% (24/30) at week 52 reported PGIS scores of 0–1, reflecting “no” to “mild” symptoms. All 19 patients reporting “severe” or “very severe” overall symptoms at baseline reported improvement following treatment. Based on PGIC, 88% (45/51) of patients at week 4 and 93% (28/30) at week 52 reported improvement from baseline in their overall symptoms (scores 1-3); 61% (31/51) and 83% (25/30) reported feeling “much better”/“very much better” (scores of 2/3) at weeks 4 and 52, respectively.
Conclusions
Treatment with bezuclastinib reduced patient-reported symptom burden and improved disease-related QoL compared with study baseline in patients with AdvSM, as assessed by MC-QoL, PGIS, and PGIC questionnaires. Improvements observed as early as the first assessment at week 4 were durable and deepened over time. These results, along with previously reported efficacy and safety data from the Apex study, further support bezuclastinib as a potential treatment for patients with AdvSM.
DISCLOSURES
Jason Gotlib, MD,MS: Incyte - Honoraria; Cogent Biosciences - Honoraria; Blueprint Medicines - Honoraria; Telios - Honoraria; Bristol Myers Squibb - Research Funding; Telios - Research Funding; Incyte - Research Funding; AbbVie - Research Funding; Merck - Research Funding; Blueprint Medicines - Research Funding; Protagonist Therapeutics - Research Funding; Cogent Biosciences - Research Funding; Blueprint Medicines - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Telios - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Response Adjudication Committee - Consultancy (Includes expert testimony)